Amgen v Regeneron Pharmaceuticals (CoA, 25 November 2025)

Date	25 November 2025
Court	CoA
Division	Luxembourg (LU)
Type of action	Appeal RoP220.1
Case number(s)	UPC_CoA_529/2024
Registry reference	UPC_CoA_529/2024
Parties	Amgen Inc. v. Regeneron Pharmaceuticals Inc.

Summary pending review. Official UPC registry metadata imported on 24 September 2026.

Official decision (PDF) · UPC registry entry

Case timeline

18 February 2026 : SANOFI-AVENTIS DEUTSCHLAND v AMGEN (CoA, 18 February 2026) UPC_CoA_528/2024 · UPC_CoA_529/2024
25 March 2026 : SANOFI-AVENTIS DEUTSCHLAND v AMGEN (CoA, 25 March 2026) UPC_CoA_528/2024 · UPC_CoA_529/2024

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

English summary awaiting review. Read the French case note.

Source and translations

Official source: Unified Patent Court registry link recorded in the record
Original language: not recorded
Translation available: no translation recorded the firm’s French record is a summary, not a translation
Date checked: not recorded

Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

UPC_CoA_529/2024 official number

Follow this case

Parties

defendantRegeneron Pharmaceuticals Inc.12 decisions in the corpus Follow this party
claimantAmgen Inc.24 decisions in the corpus Follow this party

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

25 November 2025 Amgen v Regeneron Pharmaceuticals (CoA, 25 November 2025) Appeal RoP220.1 · UPC_CoA_529/2024
18 February 2026 SANOFI-AVENTIS DEUTSCHLAND v AMGEN (CoA, 18 February 2026) Generic application · UPC_CoA_529/2024
La demande d'effet suspensif est rejetée : elle n'était pas motivée et l'arrêt attaqué, qui rejette la demande en nullité, ne modifie pas la situation du brevet et n'a rien à suspendre.
25 March 2026 SANOFI-AVENTIS DEUTSCHLAND v AMGEN (CoA, 25 March 2026) Withdrawal (RoP265) · UPC_CoA_529/2024
La cour d’appel autorise le retrait des requêtes en révision de Sanofi et Regeneron, déclare la procédure close et refuse le remboursement des frais de justice, une seule taxe ayant été payée pour deux requêtes.

What the record states

Nature of the act: Appeal RoP220.1
Appeal: Decision of the Court of Appeal.
Instance: Court of Appeal decision.

Related decisions cited in the analyses

SANOFI-AVENTIS DEUTSCHLAND v AMGEN (CoA, 25 March 2026) cited in this record
SANOFI-AVENTIS DEUTSCHLAND v AMGEN (CoA, 18 February 2026) cited in this record
Amgen v Sanofi-Aventis Deutschland (CoA, 25 November 2025) cited in this record
Samsung Electronics Benelux v Maxell (CFI, 10 August 2026) cites this decision
Angelalign Technology v Align Technology (CoA, 8 July 2026) cites this decision
PIRELLI TYRE v Sichuan Yuanxing Rubber (CFI, UPC_CFI_770/2024, 26 May 2026) cites this decision
TCL EUROPE v Corning (CFI, 1 December 2025) cites this decision

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.